Theravance Biopharma Inc

$11.12
(as of Jun 3, 9:30 AM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Theravance Biopharma Inc

Stock Price
$11.12
Ticker Symbol
TBPH
Exchange
NASDAQ

Industry Information for Theravance Biopharma Inc

Sector
Healthcare
Industry
Biotechnology

Company Description for Theravance Biopharma Inc

Website
https://www.theravance.com
Country
USA
Full Time Employees
97

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes of medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.

Fundamentals for Theravance Biopharma Inc

Market Capitalization
$518,513,472
EBITDA
$-40,726,000
Dividends per Share
P/E Ratio
Forward P/E Ratio
42.55
Earnings per Share
$-1.15
Earnings per Share Estimate Next Year
Profit Margin
-87.63%
Shares Outstanding
50,001,300
Percent Owned by Insiders
4.55%
Percent Owned by Institutions
91.10%
52-Week High
52-Week Low

Technical Indicators for Theravance Biopharma Inc

50-Day Moving Average
200-Day Moving Average
RSI
68.57
ATR
0.5

Analyst Ratings for Theravance Biopharma Inc

Strong Buy
1
Buy
1
Hold
2
Sell
0
Strong Sell
0

News About Theravance Biopharma Inc

Jun 3, 2025, 11:53 AM EST
Theravance Biopharma TBPH announced that it has entered into an agreement to sell its remaining royalty interest in net sales of Trelegy Ellipta to GSK plc GSK for $225 million in cash. See more.
Jun 2, 2025, 6:00 AM EST
Definitive agreement to result in one-time $225 million cash payment Theravance Biopharma retains rights to up to $150 million in milestones from Royalty Pharma on Trelegy Ellipta net sales in 2025 and 2026, requiring minimal to no growth over 2024 actuals to be achieved $225 million from royalty transaction announced today, in addition to the $1.1 billion upfront received in 2022, and up to $200 million in milestones (of which $50 million was received in 2025), brings total potential lifetime value from Trelegy Ellipta monetization efforts to $1.525 billion First outcome from Strategic Review Committee's ongoing efforts to maximize shareholder value; Board remains committed to returning excess capital to shareholders See more.
May 9, 2025, 12:39 PM EST
Theravance Biopharma TBPH reported first-quarter 2025 adjusted net loss of 17 cents per share, which was wider than the Zacks Consensus Estimate of a loss of 11 cents. See more.
Jan 19, 2024, 5:59 AM EST
Theravance Biopharma, Inc. See more.